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Introduction
Thyroid nodules are common in the general population
(prevalence 16–68% depending on the screening method
and population analyzed) [1]. Over 90% of the nodules
detected are benign and will never undergo transformation
[2, 3]. Accurate preoperative identification of these lesions
reduces the risk of unneeded surgery [2]. Preoperative
diagnoses of malignancy are based mainly on suspicious
ultrasonographic findings verified by cytological examina-
tion of fine-needle aspirates (FNA) [4, 5]. For cytologically
indeterminate nodules (~25%) [4, 6], molecular analyses of
the aspirates can often help to identify or exclude malig-
nancy [7]. A promising tool for this purpose is the Thyr-
oSeq v2 mutation panel [8], which can identify single-
nucleotide variants, indels, and gene fusions currently
known to drive thyroid carcinogenesis, including several
recently identified by The Cancer Genome Analysis
(TCGA) network [9]. Using a similar NGS-based approach,
we identified a novel EIF1AX mutation in a cytologically
indeterminate thyroid nodule that ultimately proved to be an
angioinvasive oncocytic thyroid carcinoma.
Methods
Case presentation
A 55-year-old Italian man underwent thyroidectomy for a
2.8-cm nodule in the right lobe that was cytologically
indeterminate (TIR 3B—oncocytic nodule in the Italian
Reporting System, corresponding to Bethesda class IV—
Hürthle cell nodule) (Fig. 1a). The nodule was solid, well-
circumscribed, and thickly encapsulated. Histological
examination revealed a predominance of oncocytic cells in
a microfollicular, trabecular pattern (Fig. 1b). Extensive
sampling identified multiple foci of capsular and vascular
invasion (Fig. 1c, d, respectively). The final diagnosis
was angioinvasive oncocytic thyroid carcinoma (pT2 Nx
Mx). It was administered a therapeutic activity of radio-
active iodine for adjuvant purpose and post-therapeutic
whole-body scan was negative. Sixteen months of follow-
up have not revealed any evidence of residual/recurrent
disease.
The patient had been diagnosed with myotonic dystrophy
type I (DM1, MIM #160900) [10], an autosomal dominant
neuromuscular disorder that also affected his mother,
brother, two sisters, and two nephews. None of the patient’s
first-degree relatives, regardless of their DM1 status, had
histories of thyroid cancer or other malignancies. Molecular
testing for DM1 revealed an abnormal CTG expansion in
the 3′ UTR of DMPK (130–350 CTG repeats; negative
values: 5–35) [11].
Molecular analysis of the thyroid nodule
FNA of the thyroid nodule was processed for cytology with
ThinPrep5000™ system (Hologic Co.). The material
remaining after cytological analysis was used for molecular
profiling. Genetic analysis was performed on the Ion
S5 system (Thermo Fisher Scientific) using two custom
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NGS multi-gene panels, which tested for single-nucleotide
variants/small indels (DNA panel) and gene fusions (RNA
panel) involving well-known thyroid cancer-related genes
(e.g., BRAF, RAS, EIF1AX, TERT, RET/PTC, and PAX8/
PPARG fusion) and others from our in-house database.
DNAs and RNAs were isolated simultaneously using the
All Prep DNA/RNA kit (QIAGEN) and measured with the
Qubit dsDNA/RNA High Sensitivity assays (Thermo Fisher
Scientific). Genes for the custom panel were selected based
on literature data [8, 9, 12] and our in-house database, and
custom primers for their targeted amplification were
designed with the Ion AmpliSeq™ Designer (Thermo
Fisher Scientific). Two libraries were created from 20 ng of
DNA and 20 ng of RNA. The targeted amplification pro-
ducts were partially digested, phosphorylated, and ligated to
Ion P1 adapter and Ion Xpress™ barcodes (Thermo Fisher
Scientific). Libraries were pooled and clonally amplified on
the Ion One Touch2 System. Sequencing was performed
using Ion S5 sequencing solution on an Ion 530 chip
(Thermo Fisher Scientific). Data were analyzed with Var-
iant Caller v5.2, annotated with Ion Reporter 5.6 and
wANNOVAR software and prioritized on the basis of their
population frequency (Minor allele frequency <0.005).
Variants were called when the position was covered by over
500 reads. The lower detection limits were set at 5% for
SNVs and 15% for small indels. Predicted variant deleter-
iousness was assessed with wANNOVAR (http://wannovar.
wglab.org/).
NGS results and the germ line/somatic status of each
variant were further validated by Sanger sequencing
analysis (as described elsewhere [13]) of formalin-fixed,
paraffin-embedded (FFPE) surgical specimens of normal
and neoplastic thyroid tissues. Primer sequences are avail-
able upon request.
Results
Our amplicon-based NGS analysis of the cytologically
indeterminate thyroid nodule FNA revealed a single somatic
mutation involving exon 6 of the eukaryotic translation
initiation factor 1A (EIF1AX) gene (NM_001412, c.C388T,
p.Gln130*) (Fig. 1e), which is located on chromosome X.
No mutations were detected in the well-known thyroid
cancer-related genes, including BRAF, RAS, RET/PTC,
PAX8/PPARG, and TERT. The EIF1AX mutation was found
in 82% of the reads. Sanger sequencing confirmed its pre-
sence in FFPE tumor slices but not in normal tissue from the
unaffected lobe (Fig. 1f). The high allele frequency (82%)
can be attributed to EIF1AX’s localization on the X chro-
mosome. The presence of two alleles probably reflects
contamination from non-tumor cells. The deleteriousness of
the EIF1AX stopgain variant was predicted by Muta-
tionTaster, CADD, DANN, Fathmm-MKL, GenoCanyon,
GERP++, phyloP100way_mammalian, pastCons20way_-
mammalian, and SiPhy_29way_logOdds (data not shown).
Sequencing of DNA from the patient’s normal thyroid tis-
sue also revealed a germ line missense mutation in CHEK2
(NM_007194.3, c.1067C>T, p.Ser356Leu), which controls
cell cycling and DNA repair.
Fig. 1 EIF1AX mutation in an oncocytic thyroid carcinoma. a Nodule
cytologically classified as indeterminate TIR 3B (oncocytic nodule) of
the Italian Reporting System corresponding to Bethesda class IV—
Hürthle cell nodule (Papanicolau-stained slide, ×500) b, c, d Definitive
histological diagnosis of angioinvasive oncocytic thyroid carcinoma
(H&E-stained sections: (b) morphological details, ×250; (c) foci of
capsular invasion, ×125; (d) foci of vascular invasion, ×125). e IGV
visualization of the EIF1AX variant (chrX:20148675G>A; p.
Gln130*). Pink and blue bars represent forward and reverse read
strands, respectively. f Sanger Sequencing validation of the EIF1AX
variant on tumor (upper panel) and normal (lower panel) thyroid tis-
sues from FFPE samples
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Discussion
EIF1AX mutations have been documented in papillary,
poorly differentiated, and anaplastic thyroid carcinomas—
with or without known driver mutations affecting RAS or
TP53—and, more recently, in benign thyroid nodules [14]
and a Hürthle cell carcinoma [15]. Most of these mutations
affected the sequence encoding the N-terminal tail of eIF1A.
[9, 12, 14], whereas the novel mutation we found, p.
Gln130*, involves the sequence encoding eIF1A’s C-
terminal. Few cancer-related mutations have been descri-
bed in this area, and the only one reported in thyroid cancer
is the A113_splice mutation [9, 12, 14], which seems to be
the most prevalent EIF1AX mutation in thyroid malignancy
[14]. Moreover, p.Gln130* is a nonsense mutation that
results in a truncated protein. Nonsense EIF1AX mutations
have been reported in cancers of the colon (p.Gly8*), eso-
phagus (p.Glu99*), breast (p.Glu117*), and vagina (p.
Glu139*) (http://www.cbioportal.org/, accessed January
2018). However, the p.Gln130* variant is the first eIF1A
nonsense mutation reported in thyroid cancer and the second
EIF1AX mutation of any type in an oncocytic thyroid car-
cinoma. Importantly, because EIF1AX is located on the X
chromosome, our male patient’s tumor harbored only trun-
cated eIF1A proteins. The potential impact of this alteration
is unclear. However, studies in yeast indicate that the C-
terminal is necessary for eIF1A’s interaction with EIF5B,
which is essential for its wild-type translation in vivo. Yeast
cells harboring eIF1A lacking the final 24 residues display
decreased rates of translation initiation in vivo [16].
The possible role of our patient’s germ line missense
mutation in CHEK2 is also unclear. Germ line mutations
involving CHEK2 have been implicated in inherited sus-
ceptibility to cancers of the breast, ovary, and prostate [17].
The p.Ser356Leu variant itself is annotated in ClinVar
(rs121908703) as having “uncertain clinical significance.”
However, none of the patient’s first-degree relatives had
histories of any type of cancer, including that of the thyroid.
Moreover, the germ line CHEK2 p.Ser356Leu was also
found in a brother of the patient’s with DM1, which is
reportedly associated with an increased risk of thyroid
cancer [18–20]. However, it was also harbored by a second
sibling without DM1 (data not shown), which also argues
against the possibility of an association between CHEK2
and DMPK gene.
In summary, we identified a novel EIF1AX mutation
(c.388C>T) in a nodule ultimately diagnosed as oncocytic
thyroid carcinoma. Functional studies are needed to better
define its role in thyroid tumorigenesis. The possibility that
it is a new driver of thyroid carcinogenesis is suggested by
the absence of other somatic driver mutations in the FNA
specimen we analyzed. It is also consistent with the fact that
the mutation results in a truncated eIF1A protein lacking the
C-terminal, which appears to play a key role in eukaryotic
translation.
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